Hepatic sinusoidal obstruction syndrome (HSOS) is a hepatic vascular disease histologically characterized by edema, necrosis, detachment of endothelial cells in small sinusoidal hepatic and interlobular veins and intrahepatic congestion, which leads to portal hypertension and liver dysfunction. In the Western world, most HSOS cases are associated with myeloablative pretreatment in a hematopoietic stem cell transplantation setting. Here we report a case of a 54 years old female patient, otherwise healthy, with no history of alcoholic ingestion, who presented with jaundice and signs of portal hypertension, including ascites and bilateral pleural effusion. She had no history of liver disease and denied any other risk factor for liver injury, e...
AIMS: Oxaliplatin is an important chemotherapeutic agent, used in the treatment of hepatic colorecta...
open8noThe authors acknowledged BolognAIL and REUSE WITH LOVE for supporting the Transplant Program ...
Adverse thromboembolic events following administration of the anti-fibrinolytic agent tranexamic aci...
Hepatic sinusoidal obstruction syndrome (HSOS) is a hepatic vascular disease histologically characte...
SummarySinusoidal obstruction syndrome (SOS) is characterized by damage to small hepatic vessels aff...
Hepatic sinusoidal obstruction syndrome (SOS) is an obliterative venulitis of the terminal hepatic v...
Sinusoidal obstruction syndrome (SOS), formerly named venoocclusive disease, is a well-known complic...
Hepatic sinusoidal obstruction syndrome (HSOS) can be caused by the intake of pyrrolizidine alkaloid...
肝窦阻塞综合征(hepatic sinusoidal obstruction syndrome,SOS)是一种少见的肝脏血管性疾病,含吡咯烷生物碱的植物为其常见致病因素,严重者可出现致命性多器官功能衰...
The presumed pathophysiological mechanism underlying sinusoidal obstruction syndrome is a drug-media...
Aim: This study aims to determine, based on existing data, whether the mechanism resulting in liver ...
Purpose: The sinusoidal obstruction syndrome (SOS) of the liver is an obliterative vasculitis that i...
Diagnosis of sinusoidal obstruction syndrome (SOS) after hematopoietic cell transplantation (HCT) is...
Saturated and unsaturated pyrrolizidine alkaloids (PAs) are present in more than 6000 plant species ...
Adverse thromboembolic events following administration of the anti-fibrinolytic agent tranexamic aci...
AIMS: Oxaliplatin is an important chemotherapeutic agent, used in the treatment of hepatic colorecta...
open8noThe authors acknowledged BolognAIL and REUSE WITH LOVE for supporting the Transplant Program ...
Adverse thromboembolic events following administration of the anti-fibrinolytic agent tranexamic aci...
Hepatic sinusoidal obstruction syndrome (HSOS) is a hepatic vascular disease histologically characte...
SummarySinusoidal obstruction syndrome (SOS) is characterized by damage to small hepatic vessels aff...
Hepatic sinusoidal obstruction syndrome (SOS) is an obliterative venulitis of the terminal hepatic v...
Sinusoidal obstruction syndrome (SOS), formerly named venoocclusive disease, is a well-known complic...
Hepatic sinusoidal obstruction syndrome (HSOS) can be caused by the intake of pyrrolizidine alkaloid...
肝窦阻塞综合征(hepatic sinusoidal obstruction syndrome,SOS)是一种少见的肝脏血管性疾病,含吡咯烷生物碱的植物为其常见致病因素,严重者可出现致命性多器官功能衰...
The presumed pathophysiological mechanism underlying sinusoidal obstruction syndrome is a drug-media...
Aim: This study aims to determine, based on existing data, whether the mechanism resulting in liver ...
Purpose: The sinusoidal obstruction syndrome (SOS) of the liver is an obliterative vasculitis that i...
Diagnosis of sinusoidal obstruction syndrome (SOS) after hematopoietic cell transplantation (HCT) is...
Saturated and unsaturated pyrrolizidine alkaloids (PAs) are present in more than 6000 plant species ...
Adverse thromboembolic events following administration of the anti-fibrinolytic agent tranexamic aci...
AIMS: Oxaliplatin is an important chemotherapeutic agent, used in the treatment of hepatic colorecta...
open8noThe authors acknowledged BolognAIL and REUSE WITH LOVE for supporting the Transplant Program ...
Adverse thromboembolic events following administration of the anti-fibrinolytic agent tranexamic aci...